208 related articles for article (PubMed ID: 12908776)
1. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
2. Pre-mixing of omega-3 fatty acid-containing liposomes enhances the drug release rate and therapeutic efficacy of anticancer drugs loaded in liposomes.
Kim EA; Choi HG; Nguyen BL; Oh SJ; Lee SB; Bae SH; Park SY; Kim JO; Kim SH; Lim SJ
J Control Release; 2024 Feb; 366():410-424. PubMed ID: 38171472
[TBL] [Abstract][Full Text] [Related]
3. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins.
Su H; Jia J; Mao Y; Zhu R; Li Z
Sci Rep; 2024 Mar; 14(1):5095. PubMed ID: 38429374
[TBL] [Abstract][Full Text] [Related]
4. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M
Sci Transl Med; 2023 May; 15(696):eabm1262. PubMed ID: 37196067
[TBL] [Abstract][Full Text] [Related]
5. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
[TBL] [Abstract][Full Text] [Related]
6. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity.
Gkionis L; Campbell RA; Aojula H; Harris LK; Tirella A
Int J Pharm; 2020 Nov; 590():119926. PubMed ID: 33010397
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2 Super Stealth Immunoliposomes for Targeted-Chemotherapy.
Canato E; Grigoletto A; Zanotto I; Tedeschini T; Campara B; Quaglio G; Toffoli G; Mandracchia D; Dinarello A; Tiso N; Argenton F; Sayaf K; Guido M; Gabbia D; De Martin S; Pasut G
Adv Healthc Mater; 2023 Nov; 12(29):e2301650. PubMed ID: 37590033
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer.
Xu G; Yang D; He C; Zhong L; Zhu J; Shu Q; Ding H; Xin W; Tong Y; Zhu X; Fang L
Cancer Chemother Pharmacol; 2023 Sep; 92(3):181-192. PubMed ID: 37378676
[TBL] [Abstract][Full Text] [Related]
9. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.
Garg A; Tisdale AW; Haidari E; Kokkoli E
Int J Pharm; 2009 Jan; 366(1-2):201-10. PubMed ID: 18835580
[TBL] [Abstract][Full Text] [Related]
10. Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes.
Hemati M; Haghiralsadat F; Jafary F; Moosavizadeh S; Moradi A
Int J Nanomedicine; 2019; 14():6575-6585. PubMed ID: 31616144
[TBL] [Abstract][Full Text] [Related]
11. Dual-Energy CT Imaging of Tumor Liposome Delivery After Gold Nanoparticle-Augmented Radiation Therapy.
Ashton JR; Castle KD; Qi Y; Kirsch DG; West JL; Badea CT
Theranostics; 2018; 8(7):1782-1797. PubMed ID: 29556356
[TBL] [Abstract][Full Text] [Related]
12. Theranostics Based on Liposome: Looking Back and Forward.
Lee W; Im HJ
Nucl Med Mol Imaging; 2019 Aug; 53(4):242-246. PubMed ID: 31456856
[TBL] [Abstract][Full Text] [Related]
13. Ligation strategies for targeting liposomal nanocarriers.
Marqués-Gallego P; de Kroon AI
Biomed Res Int; 2014; 2014():129458. PubMed ID: 25126543
[TBL] [Abstract][Full Text] [Related]
14. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.
Khan AA; Allemailem KS; Almatroodi SA; Almatroudi A; Rahmani AH
3 Biotech; 2020 Apr; 10(4):163. PubMed ID: 32206497
[TBL] [Abstract][Full Text] [Related]
15. Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes.
Gabizon A; Shmeeda H; Draper B; Parente-Pereira A; Maher J; Carrascal-Miniño A; de Rosales RTM; La-Beck NM
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004584
[TBL] [Abstract][Full Text] [Related]
16. New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.
Macpherson IR; Evans TJ
Breast Cancer (Dove Med Press); 2009 Aug; 1():1-18. PubMed ID: 24367159
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and clinical translation of liposomal delivery systems in cancer therapy.
Chen J; Hu S; Sun M; Shi J; Zhang H; Yu H; Yang Z
Eur J Pharm Sci; 2024 Feb; 193():106688. PubMed ID: 38171420
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous separation and analysis of multiple doxorubicin hydrochloride liposomes forms in serum by circular nonuniform electric field gel electrophoresis.
Xie P; Yang X; Fatima Z; Yang R; Sun H; Xing Y; Xu X; Gu J; Liu L; Li D
Anal Chim Acta; 2024 Jan; 1287():342110. PubMed ID: 38182347
[TBL] [Abstract][Full Text] [Related]
19. Replacing cholesterol with asiatic acid to prolong circulation and enhance anti-metastatic effects of non-PEGylated liposomes.
Zhang Y; Wang Y; Zhang H; Huang S; Li Y; Long J; Han Y; Lin Q; Gong T; Sun X; Zhang Z; Zhang L
J Control Release; 2024 Feb; 366():585-595. PubMed ID: 38215987
[TBL] [Abstract][Full Text] [Related]
20. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study.
Hadjidemetriou M; McAdam S; Garner G; Thackeray C; Knight D; Smith D; Al-Ahmady Z; Mazza M; Rogan J; Clamp A; Kostarelos K
Adv Mater; 2019 Jan; 31(4):e1803335. PubMed ID: 30488990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
